Normalization of overexpressed α-synuclein causing Parkinson's disease by a moderate gene silencing with RNA interference

Molecular Therapy Nucleic Acids

Volumn 4, Issue 5, 2015, Pages e241-

  Takahashi, Masaki ^a,c   Suzuki, Mari ^a   Fukuoka, Masashi ^a   Fujikake, Nobuhiro ^a   Watanabe, Shoko ^b   Murata, Miho ^b   Wada, Keiji ^a   Nagai, Yoshitaka ^a   Hohjoh, Hirohiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

Expression control; Parkinson's disease(PD); PD fibroblast; PD model fly; RNAi; SiRNA; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOUBLE STRANDED RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMBING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DROSOPHILA MELANOGASTER; EXPRESSION CONTROL RNA INTERFERENCE; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNAI THERAPEUTICS; SURVIVAL; WESTERN BLOTTING;

EID: 84943264623     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.14     Document Type: Article

References (52)

1. Parkinson, J (1817). An Essay on the Shaking Palsy. Sherwood, Neely, and Jones, London.
2. Lees, AJ, Hardy, J and Revesz, T (2009). Parkinson's disease. Lancet 373: 2055-2066.
3. Danielczyk, W (1992). Mental disorders in Parkinson's disease. J Neural Transm Suppl 38: 115-127.
4. Houlden, H and Singleton, AB (2012). The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 124: 325-338.
5. Puschmann, A (2013). Monogenic Parkinson's disease and Parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 19: 407-415.
6. Singleton, AB, Farrer, MJ and Bonifati, V (2013). The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 28: 14-23.
7. Recchia, A, Debetto, P, Negro, A, Guidolin, D, Skaper, SD and Giusti, P (2004). Alpha-synuclein and Parkinson's disease. FASEB J 18: 617-626.
8. Mizuta, I, Satake, W, Nakabayashi, Y, Ito, C, Suzuki, S, Momose, Y et al. (2006). Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 15: 1151-1158.
9. Stefanis, L (2012). α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2: a009399.
10. Wakabayashi, K, Tanji, K, Mori, F and Takahashi, H (2007). The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27: 494-506.
11. Tan, EK, Chai, A, Teo, YY, Zhao, Y, Tan, C, Shen, H et al. (2004). Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 62: 128-131.
12. Winkler, S, Hagenah, J, Lincoln, S, Heckman, M, Haugarvoll, K, Lohmann-Hedrich, K et al. (2007). Alpha-Synuclein and Parkinson disease susceptibility. Neurology 69: 1745-1750.
13. Mata, IF, Shi, M, Agarwal, P, Chung, KA, Edwards, KL, Factor, SA et al. (2010). SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67: 1350-1356.
14. Polymeropoulos, MH, Lavedan, C, Leroy, E, Ide, SE, Dehejia, A, Dutra, A et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
15. Krüger, R, Kuhn, W, Müller, T, Woitalla, D, Graeber, M, Kösel, S et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
16. Zarranz, JJ, Alegre, J, Gómez-Esteban, JC, Lezcano, E, Ros, R, Ampuero, I et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
17. McCarthy, JJ, Linnertz, C, Saucier, L, Burke, JR, Hulette, CM, Welsh-Bohmer, KA et al. (2011). The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics 12: 59-64.
18. Singleton, AB, Farrer, M, Johnson, J, Singleton, A, Hague, S, Kachergus, J et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
19. Farrer, M, Kachergus, J, Forno, L, Lincoln, S, Wang, DS, Hulihan, M et al. (2004). Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 55: 174-179.
20. Theuns, J and Van Broeckhoven, C (2008). alpha-Synuclein gene duplications in sporadic Parkinson disease. Neurology 70: 7-9.
21. Chiba-Falek, O, Lopez, GJ and Nussbaum, RL (2006). Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 21: 1703-1708.
22. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
23. Sharp, PA (1999). RNAi and double-strand RNA. Genes Dev 13: 139-141.
24. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
25. Paddison, PJ, Caudy, AA, Bernstein, E, Hannon, GJ and Conklin, DS (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958.
26. Sui, G, Soohoo, C, Affar, el B, Gay, F, Shi, Y, Forrester, WC et al. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99: 5515-5520.
27. Yu, JY, DeRuiter, SL and Turner, DL (2002). RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 99: 6047-6052.
28. Rodriguez-Lebron, E and Paulson, HL (2006). Allele-specific RNA interference for neurological disease. Gene Ther 13: 576-581.
29. Hohjoh, H (2013). Disease-causing allele-specific silencing by RNA interference. Pharmaceuticals (Basel) 6: 522-535.
30. Ohnishi, Y, Tokunaga, K, Kaneko, K and Hohjoh, H (2006). Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. J RNAi Gene Silencing 2: 154-160.
31. Ohnishi, Y, Tamura, Y, Yoshida, M, Tokunaga, K and Hohjoh, H (2008). Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 3: e2248.
32. Huang, H, Qiao, R, Zhao, D, Zhang, T, Li, Y, Yi, F et al. (2009). Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res 37: 7560-7569.
33. Takahashi, M, Watanabe, S, Murata, M, Furuya, H, Kanazawa, I, Wada, K et al. (2010). Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl Acad Sci USA 107: 21731-21736.
34. Noland, CL and Doudna, JA (2013). Multiple sensors ensure guide strand selection in human RNAi pathways. RNA 19: 639-648.
35. Feany, MB and Bender, WW (2000). A Drosophila model of Parkinson's disease. Nature 404: 394-398.
36. Roy, B and Jackson, GR (2014). Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet 23: 3008-3023.
37. Ui-Tei, K, Naito, Y, Takahashi, F, Haraguchi, T, Ohki-Hamazaki, H, Juni, A et al. (2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32: 936-948.
38. Hohjoh, H (2002). RNA interference (RNA(i)) induction with various types of synthetic oligonucleotide duplexes in cultured human cells. FEBS Lett 521: 195-199.
39. Gorbatyuk, OS, Li, S, Nash, K, Gorbatyuk, M, Lewin, AS, Sullivan, LF et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 18: 1450-1457.
40. Khodr, CE, Sapru, MK, Pedapati, J, Han, Y, West, NC, Kells, AP et al. (2011). An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 1395: 94-107.
41. Cabrejo, L, Guyant-Maréchal, L, Laquerrière, A, Vercelletto, M, De la Fournière, F, Thomas-Antérion, C et al. (2006). Phenotype associated with APP duplication in five families. Brain 129(Pt 11): 2966-2976.
42. Rovelet-Lecrux, A, Hannequin, D, Raux, G, Le Meur, N, Laquerrière, A, Vital, A et al. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38: 24-26.
43. Sleegers, K, Brouwers, N, Gijselinck, I, Theuns, J, Goossens, D, Wauters, J et al. (2006). APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129(Pt 11): 2977-2983.
44. Inoue, K, Osaka, H, Sugiyama, N, Kawanishi, C, Onishi, H, Nezu, A et al. (1996). A duplicated PLP gene causing Pelizaeus-Merzbacher disease detected by comparative multiplex PCR. Am J Hum Genet 59: 32-39.
45. Wolf, NI, Sistermans, EA, Cundall, M, Hobson, GM, Davis-Williams, AP, Palmer, R et al. (2005). Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 128(Pt 4): 743-751.
46. Lupski, JR, de Oca-Luna, RM, Slaugenhaupt, S, Pentao, L, Guzzetta, V, Trask, BJ et al. (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66: 219-232.
47. Raeymaekers, P, Timmerman, V, Nelis, E, De Jonghe, P, Hoogendijk, JE, Baas, F et al. (1991). Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1: 93-97.
48. Tal, M, Wetzler, M, Josefberg, Z, Deutch, A, Gutman, M, Assaf, D et al. (1988). Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 48: 1517-1520.
49. al-Kasspooles, M, Moore, JH, Orringer, MB and Beer, DG (1993). Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54: 213-219.
50. Tamura, Y, Yoshida, M, Ohnishi, Y and Hohjoh, H (2009). Variation of gene silencing involving endogenous microRNA in mammalian cells. Mol Biol Rep 36: 1413-1420.
51. Takahashi, M, Eda, A, Fukushima, T and Hohjoh, H (2012). Reduction of type IV collagen by upregulated miR-29 in normal elderly mouse and klotho-deficient, senescence-model mouse. PLoS One 7: e48974.
52. Fujikake, N, Nagai, Y, Popiel, HA, Okamoto, Y, Yamaguchi, M and Toda, T (2008). Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283: 26188-26197.